coronary heart disease
glycemical profile

How to Cite

Gridneva, O. V. (2023). DYNAMICS OF CHARACTERISTICS OF THE GLYCEMICAL PROFILE OF PATIENTS WITH CORONARY HEART DISEASE AND OBESITY AFTER TREATMENT. Clinical and Preventive Medicine, (4), 27-36. https://doi.org/10.31612/2616-4868.4(26).2023.04


Introduction. Cardiovascular diseases (CVD) have the status of an epidemic, as they have high levels of prevalence and are the main cause of disability and mortality both in Ukraine and in the world and cause a significant increase in health care costs. Among all CVDs, coronary heart disease (CHD) ranks first. Many studies confirm a high percentage of CHD among all CVDs, especially in comorbidity with hyperlipidemia and obesity. Therefore, when treating CHD disease with obesity, it is necessary to take into account the effectiveness of the applied pharmacological agents and determine the dynamics of pharmacological intervention.

The aim. To determine the dynamics of indicators of the glycemic profile in the comorbid course of CHD and obesity after the treatment.

Materials and methods. It was conducted a randomized controlled single-center prospective study case-control, which is based on the analysis of the results of 130 people aged 25–85 were examined, who were divided into 3 groups: 70 persons (main group) with CHD on the background of obesity and 35 people with isolated coronary artery disease (comparison group) and control group (25 practically healthy people). The studied groups were randomized by age and gender.

Results. Before treatment, a probable predominance of daily glucose levels was determined in patients main group to the patients comparison group and controls. According to the results of the glucose tolerance test (GTT), an improbable excess of fasting glucose levels and after a glucose load was determined in CHD with obesity (respectively 5.64±1.92 and 7.08±2.25 mmol/l) compared to the isolated of CHD (respectively 5, 15±2.22 (p=0.791) and 6.20±3.15 (p=0.403) mmol/l) and control group (respectively 5.32±0.49 (p=0.685) and 5.42±0, 51 (p<0.001) mmol/l). After treatment, recovery of blood glucose levels was determined.

Conclusions. It was established that the characteristics of the dynamics of glucose metabolism indicators can be used as an indicator of the effectiveness of the treatment in the comorbidity of obesity and CHD. The obtained results indicate that the characteristics of glucose metabolism in the comorbidity of CHD and obesity must be taken into account to ensure therapeutic and preventive measures.



Zhou, D., Xi, B., Zhao, M., Wang, L., Veeranki, S. P. (2018). Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep., 8(1), 9418. doi: https://doi.org/10.1038/s41598-018-27377-2

Yusuf, S., Joseph, P., Rangarajan, S., Islam, S., Mente, A., Hystad, P., Brauer, M., Kutty, V. R., Gupta, R., Wielgosz, A., AlHabib, K. F., Dans, A., Lopez-Jaramillo, P., Avezum, A., Lanas, F., Oguz, A., Kruger, I. M., Diaz, R., Yusoff, K., Mony, P., Chifamba, J., Yeates, K., Kelishadi, R., Yusufali, A., Khatib, R., Rahman, O., Zatonska, K., Iqbal, R., Wei, L., Bo, H., Rosengren, A., Kaur, M., Mohan, V., Lear, S. A., Teo, K. K., Leong, D., O'Donnell, M., McKee, M., Dagenais, G. (2020). Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet, 395(10226), 795–808. doi: https://doi.org/10.1016/S0140-6736(19)32008-2

Liu, S., Li, Y., Zeng, X., Wang, H., Yin, P., Wang, L., Liu, Y., Liu, J., Qi, J., Ran, S., Yang, S., Zhou, M. (2019). Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study. JAMA Cardiol, 4(4), 342–352. doi: https://doi.org/10.1001/jamacardio.2019.0295

Mensah, G. A, Roth, G. A., Fuster, V. (2019). The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol, 74(20), 2529–2532. doi: https://doi.org/10.1016/j.jacc.2019.10.009

GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396(10258), 1204–1222. doi: https://doi.org/10.1016/S0140-6736(20)30925-9

GBD 2017 DALYs and HALE Collaborators (2018). Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392(10159), 1859–1922. doi: https://doi.org/10.1016/S0140-6736(18)32335-3

Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., & Fuster, V., GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group (2020). Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol, 76(25), 2982–3021. doi: https://doi.org/10.1016/j.jacc.2020.11.010

GBD 2016 Risk Factors Collaborators (2017). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390(10100), 1345–1422. doi: https://doi.org/10.1016/S0140-6736(17)32366-8

Global BMI Mortality Collaboration, Di Angelantonio E., Bhupathiraju Sh. N. et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016. Vol. 388(10046). Р. 776–86. doi: https://doi.org/10.1016/S0140-6736(16)30175-1

Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu, Y., Hajifathalian, K., Ezzati, M., Woodward, M., Rimm, E. B., Danaei, G. (2014). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet, 383(9921), 970–83. doi: https://doi.org/10.1016/S0140-6736(13)61836-X

Kivimäki, M., Kuosma, E., Ferrie, J. E., Luukkonen, R., Nyberg, S. T., Alfredsson, L., & Jokela, M. (2017). Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health, 2(6), e277–e285. doi: https://doi.org/10.1016/S2468-2667(17)30074-9

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., & Bax, J. J., ESC Scientific Document Group (2020). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J, 41(3), 407–477. doi: https://doi.org/10.1093/eurheartj/ehz425

Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., & Shaw, L. J. (2021). 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 144(22), e368–e454. doi: https://doi.org/10.1161/CIR.0000000000001029

Hebebrand, J., Holm, J. C., Woodward, E., Baker, J. L., Blaak, E., Durrer-Schutz, D., & Yumuk, V. A. (2017). А proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk. Obes Facts, 10(4), 284–307. doi: https://doi.org/10.1159/000479208

National Institutes of Health, NHLBI Obesity Education Initiative, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity (2000). The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, 94 p. URL: https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf

Evstratova, Y. N., Mukhannad Alshbul (2015). Fyzycheskaia reabylytatsyia bolnыkh yshemycheskoi bolezniu serdtsa s narushenyem tolerantnosty k hliukoze y abdomynalnыm ozhyrenyem [Physical rehabilitation of patients with ischemic heart disease with impaired glucose tolerance and abdominal obesity]. Naukovyi chasopys Natsionalnoho pedahohichnoho universytetu imeni M. P. Drahomanova. Seriia 15: Naukovo-pedahohichni problemy fizychnoi kultury (fizychna kultura i sport) [Scientific journal of the National Pedagogical University named after M. P. Drahomanov. Series 15: Scientific and pedagogical problems of physical culture (physical culture and sports)], 10, 55–58. (In Russian).

Mankovskyi, H. B. (2018). Dyahnostyka narushenyi uhlevodnoho obmena u bolnыkh s yshemycheskoi bolezniu serdtsa [Diagnosis of impaired carbohydrate metabolism in patients with ischemic heart disease]. Medychni perspektyvy [Medical perspectives], 23(2), 46–52. doi: https://doi.org/10.26641/2307-0404.2018.2.133698 (In Ukrainian).

Lapovets, L. Ye., Bashta, H. V., Shchurko, M. M., Kachuk, S. O. (2019). Osoblyvosti zmin klirensu kreatyninu pry ishemichnii khvorobi sertsia, uskladnenii ozhyrinniam [Peculiarities of changes in creatinine clearance in coronary heart disease complicated by obesity]. Visnyk problem biolohii i medytsyny [Herald of problems of biology and medicine], 3(152), 143–146. doi: https://doi.org/10.29254/2077-4214-2019-3-152-143-146 (In Ukrainian).

Kadykova, O. I. (2018). Dyferentsiiovanyi pidkhid do vykorystannia standartnoi terapii khronichnoi sertsevoi nedostatnosti u khvorykh na ishemichnu khvorobu sertsia y ozhyrinnia [A differentiated approach to the use of standard therapy for chronic heart failure in patients with coronary heart disease and obesity]. J. Clin. Exp. Med. Res, 6(1), 113–120. (In Ukrainian).

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.